機構股票研究
機構股票研究
機構股票研究
機構股票研究 
 
Page | 1 | PHILLIP SECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ) 
回檔現買入時機 
 
中國大陸
中國大陸
中國大陸
中國大陸 | 醫藥
醫藥
醫藥
醫藥 | 公司研報
公司研報
公司研報
公司研報 
 
 
 
29 JUNE 2018 
 
投資概要
投資概要
投資概要
投資概要 
 
近期市場波動加劇，公司股價回落，出現買入機會。我們重申公司基本面情況良好，
一季度營業收入同比增長7.26%，淨利潤同比增速11.18%，經營活動產生的現金淨流量
同比增加137.75%。公司銷售人效在混改後改善明顯。同時，建議關注公司醫療業務進
展。我們預測2018年EPS為3.4元/股，維持33倍目標市盈率，目標股價112.0元。(現價
截至6月27日) 
 
公司概況
公司概況
公司概況
公司概況 
 
行業增速放緩
行業增速放緩
行業增速放緩
行業增速放緩，惟龍頭強者恒強
惟龍頭強者恒強
惟龍頭強者恒強
惟龍頭強者恒強。中國商務部發佈的《2017 年藥品流通行業運行統計
分析報告》顯示，醫藥批發企業增速放緩，前100 位藥品批發企業主營業務收入同比
增長8.4%，下降5.6 個百分點。雲南省醫藥公司的批發業務年營收144.9 億元，在藥
品批發企業排名中，名列第16 位，是區域龍頭流通企業。未來，國家各項醫改政策相
繼發佈實施，藥品流通行業將進入深度調整期，區域性藥品流通企業將加速跨區域並
購，實現強者恒強。 
 
混改之後銷售人員效率提升
混改之後銷售人員效率提升
混改之後銷售人員效率提升
混改之後銷售人員效率提升。2010-2016年，銷售人員人均效率有所下降。2017年，公
司控股股東雲南白藥控股有限公司引進民營企業新華都和江蘇魚躍作為戰略投資者，
進一步加深混合所有制改革。2017年銷售人員效率已見提高，銷售人員人均收入貢獻
同比上升9.62%（2016年增速4.19%），人均淨利潤同比增速達到2.38%（2016年增速
1.6%）。隨著混改效果進一步顯現，預計公司有望保持良好的運營效率。 
 
圖表：銷售人員人均貢獻（萬元） 
 
2012
2013
2014
2015
2016
2017
銷售人員數量/人 
1976
2403
3780
4970
5155
5102
占從業人員總數比例 
46.23%
46.80%
53.72%
60.97%
61.40%
61.51%
人均銷售額/萬元 
692.65 
658.13 
497.73 
417.27 
434.74 
476.57 
YoY 
16.77%
-4.98%
-24.37%
-16.17%
4.19%
9.62%
人均淨利潤/萬元 
80.09 
96.61 
66.30 
55.75 
56.64 
57.99 
YoY 
26.12%
20.63%
-31.37%
-15.91%
1.60%
2.38%
工業收入人均貢獻/萬元 
289.57 
284.75 
216.66 
184.72 
176.15 
195.26 
YoY 
26.00%
-1.67%
-23.91%
-14.74%
-4.64%
10.85%
流通收入人均貢獻/萬元 
395.75 
373.38 
280.11 
231.93 
257.53 
279.96 
YoY 
13.47%
-5.65%
-24.98%
-17.20%
11.04%
8.71%
Source: Company, Phillip Securities 
 
醫療業務值得期待
療業務值得期待
療業務值得期待
療業務值得期待。公司公佈的投資者訪談顯示，順應雲南省要把雲南建設成健康生
活目的地的地區戰略，公司作為雲南省和昆明市的龍頭醫藥健康企業，有望得到政府
政策的支援和傾斜。公司拓展醫療業務的思路包括，尋找例如高等院校端的醫療資
源，或結合白藥的品牌特點，向骨傷科診療方向拓展。建議關注相關進展。 
 
 
 
 
增持
增持
增持
增持 
現價 RMB104.03 
(現價截至6 月27 日) 
目標價 RMB112.0 (+7.66%) 
 
公司資料
公司資料
公司資料
公司資料 
普通股股東 (百萬股) : 
1,041.4
市值 (人民幣百萬元) : 
110,700
52 周 最高價/最低價 (人民幣) : 
120.05/84.35
 
 
主要股東
主要股東
主要股東
主要股東， % 
Yunnan Baiyao Holdings 
41.52
Yunnan Hehe 
10.09
Pingan 
9.36
HK Connect 
6.51
New Huadu 
3.39
CSF 
2.56
 
股價表現
股價表現
股價表現
股價表現% 
1 個月
個月
個月
個月
3 個月
個月
個月
個月
1 年
雲南白藥 
-12.18
4.40
9.00
上證指數 
-10.27
-10.99
-11.84
 
股價
股價
股價
股價 & 上證指數
上證指數
上證指數
上證指數 
 
Source: Aastocks, Phillip Securities (HK) Research 
 
財務資料
財務資料
財務資料
財務資料 
RMB/mn 
FY16
FY17
FY18E
FY19E
Net Sales 
22,411
24,315
26,911
29,263
Net Profit 
2,931
3,133
3,536
4,005
EPS, RMB 
2.80 
3.02 
3.40 
3.85 
PER, x 
34.36 
31.86 
28.34 
25.02 
BVPS, RMB
15.10 
17.32 
19.97 
22.85 
P/BV, x 
6.37 
5.56 
4.82 
4.21 
ROE, %  
18.50 
17.27 
17.00 
16.83 
Source: Wind, Phillip Securities Est. 
 
周霖
周霖
周霖
周霖 (2277 6515) 
euruszhou@phillip.com.hk 
 
 
 
 
 
 
 
 
Page | 2 | PHILLIP SECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
估值和風險
估值和風險
估值和風險
估值和風險 
 
我們的模型顯示目標價為
我們的模型顯示目標價為
我們的模型顯示目標價為
我們的模型顯示目標價為112.0元。我們預測未來各分部業務增速，假設2018年
EPS預測至3.4元/股，維持33倍目標市盈率，目標股價112.0元。風險包括
風險包括
風險包括
風險包括：銷售
費用上升；流通業務受兩票制影響；健康產品競爭激烈；混改效果不及預期。 
 
圖表：業務分部收入、增速及假設(RMB'000) 
 
2014 
2015 
2016 
2017 
2018E 
2019E 
營業收入
營業收入
營業收入
營業收入 
18,814,366.37 
20,738,126.21 
22,410,654.40 
24,314,614.04 
26,910,549.80 
29,263,000.50 
YOY
18.97%
10.22%
8.06%
8.50%
10.68%
8.74%
醫藥流通
醫藥流通
醫藥流通
醫藥流通 
10,588,189.27 
11,527,074.37 
13,275,890.44 
14,283,554.30 
15,283,403.10 
16,429,658.34 
YOY
18.01%
8.87%
15.17%
7.59%
7.00%
7.50%
GPM
6.54%
6.36%
7.84%
7.29%
Weight
56.28%
55.58%
59.24%
58.74%
56.79%
56.14%
醫藥工業
醫藥工業
醫藥工業
醫藥工業 
8,189,759.72 
9,180,400.94 
9,080,384.24 
9,962,024.66 
11,627,146.70 
12,833,342.17 
YOY
19.69%
12.10%
-1.09%
9.71%
16.71%
10.37%
GPM
60.65%
60.83%
62.10%
65.61%
63.86%
64.73%
--藥品事業部 
4,977,240.00 
5,095,940.00 
4,917,690.00 
5,043,510.00 
5,144,380.20 
5,272,989.71 
YOY
12.58%
2.38%
-3.50%
2.56%
2.00%
2.50%
Weight
26.45%
24.57%
21.94%
20.74%
19.12%
18.02%
--健康產品事業部 
2,753,320.00 
3,354,510.00 
3,756,770.00 
4,361,150.00 
5,015,322.50 
5,817,774.10 
YOY
32.66%
21.84%
11.99%
16.09%
15.00%
16.00%
Weight
14.63%
16.18%
16.76%
17.94%
18.64%
19.88%
--中藥資源事業部 
450,520.00 
651,400.00 
943,950.00 
1,162,870.00 
1,395,444.00 
1,660,578.36 
YOY
30.19%
44.59%
44.91%
23.19%
20.00%
19.00%
Weight
2.39%
3.14%
4.21%
4.78%
5.19%
5.67%
Source: Company, Phillip Securities 
 
圖表：同業比較 
Code 
Firm 
Mkt.Cap/mn ROE(%)
GPM(%) 
NPM(%) 
PE 
 
1Q18
17
16
1Q18
17
16
17A
18E
19E
000538.SZ 雲南白藥 
110,700.79 
18.63
29.96
30.7
29.38
12.81
12.97
13.17
35.2
30.78
26.89
A shares 
Max 
112,119.68 
30.36
91.67
90.17
90.23
36.43
28.08
29.69
84.06
63.11
47.72
Medium 
45,002.75 
17.6
46.7
44.15
46.83
15.24
14.38
15.12
31.02
24.62
21.13
Average 
57,717.35 
17.92
54.59
54.27
54.51
19.07
16.78
16.55
37.5
32.21
26.6
600518.SH 康美藥業 
112,119.68 
13.41
28.66
29.68
29.23
15.63
15.61
15.56
27.34
22.55
18.55
600436.SH 片仔癀 
67,836.99 
21.16
45.85
42.65
48.26
26.96
21.24
22.24
84.06
63.11
47.72
600332.SH 白雲山 
58,869.59 
11.39
37.81
37.05
32.42
13.53
10.21
7.85
29.53
23.63
20.55
600085.SH 同仁堂 
50,223.24 
12.55
47.55
45.65
45.39
14.86
13.16
13.06
49.37
44.5
39.78
600566.SH 濟川藥業 
39,782.26 
30.36
84.37
84.66
84.95
22.37
22.12
20.37
32.52
24.62
19.62
600535.SH 天士力 
39,041.92 
16.57
33.71
35.53
35.82
9.62
8.82
8.84
28.36
24.49
21.13
002773.SZ 康弘藥業 
34,586.97 
19.98
91.67
90.17
90.23
29.85
23.52
20.05
53.69
41.23
31.83
000423.SZ 東阿阿膠 
34,401.53 
22.46
66.49
64.6
66.59
36.43
28.08
29.69
16.83
15
13.36
603858.SH 步長製藥 
29,610.57 
12.72
79.86
81.98
82.82
8.6
12.06
14.67
18.08
--
--
HK shares 
 
 
Page | 3 | PHILLIP SECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
Max 
58,869.59 
22.6
74.87
77.68
81.66
43.37
39.87
40.42
27.75
23.55
20.34
Medium 
10,824.68 
12.92
56.34
62.87
64.54
28.45
21.38
18.24
22.77
17.8
15.68
Average 
15,572.27 
14.19
56.34
61.61
62.33
28.45
20.88
20.23
20.99
17.1
14.65
0874.HK 
白雲山 
58,869.59 
11.39
37.81
37.05
32.42
13.53
10.21
7.85
22.45
17.86
15.56
0570.HK 
中國中藥 
28,232.46 
9.74
--
55.79
57.98
--
15.72
16.63
24.28
20.37
17.11
2186.HK 
綠葉製藥 
22,903.14 
14.87
--
77.68
81.66
--
25.67
30.6
23.49
19.88
17.29
1666.HK 
同仁堂科技 
13,361.09 
14.46
--
50.26
50.71
--
19.3
18.24
20.17
17.74
15.8
3613.HK 
同仁堂國藥 
11,291.19 
21.23
74.87
72.39
73.33
43.37
39.87
40.42
27.75
23.55
20.34
2877.HK 
神威藥業 
10,358.17 
7.89
--
66.01
64.54
--
23.47
29.49
23.09
16.58
14.1
1681.HK 
康臣藥業 
5,398.26 
22.6
--
73.99
74.46
--
25.4
26.09
13.71
11.42
9.66
0587.HK 
華瀚健康 
3,167.48 
--
--
--
--
--
--
--
--
--
--
0932.HK 
順騰國際控股
1,234.31 
--
--
--
71.14
--
--
5.35
--
--
--
3737.HK 
中智藥業 
906.98 
11.33
--
59.73
54.68
--
7.4
7.36
13.03
9.38
7.36
Source: Wind (as at Jun 27), Phillip Securities 
 
 
 
 
 
 
 
Page | 4 | PHILLIP SECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
 
財務報告
財務報告
財務報告
財務報告 
 
FYE 
FY2015
FY2016
FY2017
FY2018E
FY2019E
Valuation Ratios 
 
 
 
 
  
Price to Earnings (P/E) 
36.17 
34.36 
31.86 
28.34 
25.02 
Price to Book (P/B) 
7.46 
6.37 
5.56 
4.82 
4.21 
Per Share Data (RMB) 
 
 
 
 
  
EPS 
2.66 
2.80 
3.02 
3.40 
3.85 
Book Value Per Share 
12.90 
15.10 
17.32 
19.97 
22.85 
Dividend Per Share 
0.60 
0.80 
1.50 
1.70 
1.92 
Growth (%) 
 
 
 
 
  
Revenue 
10.22 
8.06 
8.50 
10.68 
8.74 
Gross Profit 
30.53 
29.86 
31.19 
31.89 
32.66 
Operating Income 
11.96 
4.78 
9.06 
12.89 
12.65 
Net Profit 
10.34 
6.36 
6.88 
12.87 
13.28 
Margins (%) 
 
 
 
 
  
Gross Profit Margin 
30.53 
29.86 
31.19 
31.89 
32.66 
Operating Profit Margin 
15.28 
14.81 
14.89 
15.19 
15.74 
Net Profit Margin 
13.29 
13.08 
12.88 
13.14 
13.69 
Profitability 
 
 
 
 
  
ROE (%) 
20.37 
18.50 
17.27 
17.00 
16.83 
ROA (%) 
14.28 
11.92 
11.31 
11.22 
11.11 
  
 
 
 
 
  
FYE 
FY2015
FY2016
FY2017
FY2018E
FY2019E
Income Statement (RMB Mn) 
 
 
 
  
Revenue 
20,738.1 
22,410.7 
24,314.6 
26,910.5 
29,263.0 
- Cost of Goods Sold 
-14,405.9 
-15,718.0 
-16,731.6 
-18,329.8 
-19,707.0 
Gross Income 
6,332.2 
6,692.7 
7,583.0 
8,580.7 
9,556.0 
- Operating Expenses 
-3,164.0 
-3,372.9 
-4,100.4 
-4,493.2 
-4,951.3 
Operating Income 
3,168.2 
3,319.8 
3,620.7 
4,087.5 
4,604.7 
+ Net Non-Operating Gain/Loss
47.1 
77.7 
1.1 
0.0 
0.0 
Pretax Income 
3,215.3 
3,397.5 
3,621.8 
4,087.5 
4,604.7 
- Income Tax Expenses 
-459.8 
-466.6 
-489.3 
-551.7 
-599.4 
- Minority Interest 
-15.3 
11.0 
-12.4 
-13.8 
-15.0 
Net Profit 
2,755.6 
2,930.9 
3,132.5 
3,535.8 
4,005.3 
Source: Company, Wind, Phillip Securities (HK) Research Estimates 
 (財務資料截至2018 年6 月27 日) 
  
 
 
 
 
 
 
 
PHILL
 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
PHILLIP RESEARCH STOCK SELECTION SYSTEMS 
 
We do not base our recommendations entirely on the above quantitative return bands.  We consider qualitative factors like (but not limited to) a stock's 
risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones 
surrounding the stock, before making our final recommendation 
 
GENERAL DISCLAIMER 
This publication is prepared by Phillip Securities (Hong Kong) Ltd (“Phillip Securities”). By receiving or reading this publication, you agree to be bound by the terms and 
limitations set out below. 
 
This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or 
consequential loss arising from any use of material contained in this publication. 
 
The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, 
forecasts, projections, expectations and opinions (collectively the “Research”) contained in this publication are based on such information and are expressions of belief only. 
Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or 
verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any 
responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip 
Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even 
if it has been advised of the possibility of such damages. 
 
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without 
prior notice. 
 
This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any 
particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a 
financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, 
before making a commitment to invest in any of such products. 
This publication should not be relied upon as authoritative without further being subject to the recipient’s own independent verification and exercise of judgment. The fact 
that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in 
this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant 
risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are 
understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any 
product should not be considered to be a disclosure of all risks or a complete discussion of such risks. 
 
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research 
should take into account existing public information, including any registered prospectus in respect of such security. 
 
Disclosure of Interest 
Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this 
report. 
Firm’s Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or 
more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation. 
 
Availability 
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such 
distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or 
other requirement, or penalty for contravention of such requirements within such jurisdiction. 
 
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited (“PSHK”) believed to be accurate. PSHK does not bear responsibility for any 
loss occasioned by reliance placed upon the contents hereof.  PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of 
different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.   
© 
2018 Phillip Securities (Hong Kong) Limited 
 
Contact Information (Regional Member Companies) 
Total Return 
Recommendation 
Rating 
Remarks 
>+20% 
Buy 
1 
>20% upside from the current price 
+5% to +20% 
Accumulate 
2 
+5% to +20%upside from the current price 
-5% to +5% 
Neutral 
3 
Trade within  ± 5% from the current price 
-5% to -20% 
Reduce 
4 
-5% to -20% downside from the current price 
<-20% 
Sell 
5 
>20%downside from the current price 
 
 
 
PHILL
 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
SINGAPORE 
Phillip Securities Pte Ltd 
Raffles City Tower 
250, North Bridge Road #06-00 
Singapore 179101 
Tel : (65) 6533 6001 
Fax : (65) 6535 6631 
Website: www.poems.com.sg 
MALAYSIA 
Phillip Capital Management Sdn Bhd 
B-3-6 Block B Level 3 Megan Avenue II, 
No. 12, Jalan Yap Kwan Seng, 50450 
Kuala Lumpur 
Tel (603) 21628841 
Fax (603) 21665099 
Website: www.poems.com.my 
 
HONG KONG 
Phillip Securities (HK) Ltd 
Exchange Participant of the Stock Exchange of Hong Kong 
11/F United Centre 95 Queensway 
Hong Kong 
Tel (852) 22776600 
Fax (852) 28685307 
Websites: www.phillip.com.hk 
 
JAPAN 
PhillipCapital Japan K.K. 
Nagata-cho Bldg., 
8F, 2-4-3 Nagata-cho, 
Chiyoda-ku, Tokyo 100-0014 
Tel (81-3) 35953631 
Fax (81-3) 35953630 
Website:www.phillip.co.jp 
 
INDONESIA 
PT Phillip Securities Indonesia 
ANZ Tower Level 23B, 
Jl Jend Sudirman Kav 33A 
Jakarta 10220 – Indonesia 
Tel (62-21) 57900800 
Fax (62-21) 57900809 
Website:www.phillip.co.id 
 
CHINA 
Phillip Financial Advisory (Shanghai) Co. Ltd 
No 436 Hengfeng Road, 
Greentech Unit 604, 
Postal code 200070 
Tel (86-21) 51699400 
Fax (86-21) 63532643 
Website: www.phillip.com.cn 
 
THAILAND 
Phillip Securities (Thailand) Public Co. Ltd 
15th Floor, Vorawat Building, 
849 Silom Road, Silom, Bangrak, 
Bangkok 10500 Thailand 
Tel (66-2) 6351700 / 22680999 
Fax (66-2) 22680921 
Websitewww.phillip.co.th 
 
FRANCE 
King & Shaxson Capital Limited 
3rd Floor, 35 Rue de la Bienfaisance 75008 
Paris France 
Tel (33-1) 45633100 
Fax (33-1) 45636017 
Website: www.kingandshaxson.com 
 
UNITED KINGDOM 
King & Shaxson Capital Limited 
6th Floor, Candlewick House, 
120 Cannon Street, 
London, EC4N 6AS 
Tel (44-20) 7426 5950 
Fax (44-20) 7626 1757 
Website: www.kingandshaxson.com 
 
UNITED STATES 
Phillip Futures Inc 
141 W Jackson Blvd Ste 3050 
The Chicago Board of Trade Building 
Chicago, IL 60604 USA 
Tel +1.312.356.9000 
Fax +1.312.356.9005 
 
AUSTRALIA 
PhillipCapital Australia 
Level 12, 15 William Street, 
Melbourne, Victoria 3000, Australia 
Tel (613) 96188238 
Fax (613) 92002272 
Website: www.phillipcapital.com.au 
 
 
